Cetuximab and panitumumab—both anti‐EGFR monoclonal antibodies—are commonly used as first‐line therapy in metastatic CRC patients who are RAS and BRAF wild‐type and HER2‐positive (defined as IHC 3+ or IHC 2+ with FISH positivity) [90]. The gene discussed is EGFR; the disease is colorectal carcinoma.